Search results
Your search for process/pmg6 returned no results
Showing 1456 to 1470 of 2854 results for process
Showing 1456 to 1470 of 2854 results for process
guidance How we develop HealthTech guidance Get a HealthTech evaluated Process timeline for HealthTech guidance NICE: backing the...
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Uterine artery embolisation for treating adenomyosis (HTG324)
Evidence-based recommendations on uterine artery embolisation for treating adenomyosis. This involves injecting small particles to block the blood supply to the adenomyosis (thickening of the womb lining).
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Read NICE's statement on modern slavery and human trafficking.
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.
View recommendations for HTG89Show all sections
Sections for HTG89
In development Reference number: GID-TA11221 Expected publication date: TBC